AIM COVID-19 vaccine achieved critical progress in industrialization

2021-07-21 Source:AIM Vaccine

Ningbo Rong’an Biological Pharmaceutical Co., Ltd, the wholly owned subsidiary of AIM Vaccine has recently obtained Approval Form of Clinical Trial as approved and issued by National Medical Products Administration. Meanwhile, clinical test for inactivated COVID-19 vaccine (Vero cell) is to be initiated. It is the second COVID-19 vaccine obtained clinical approval by AIM Vaccine following mRNA COVID-19 vaccine.

Furthermore, our advanced bio-safety workshop of inactivated COVID-19 vaccine of at Ningbo Free Trade Zone has been constructed. Its anticipated annual output will be up to 500 million dosages. Meanwhile, the advanced bio-safety laboratory at the same plant is also under accelerated construction.